The FDA on April 19, 2019, approved KEYTRUDA® (Pembrolizumab) plus INLYTA® (Axitinib) for the first-line treatment of patients with advanced Renal Cell Carcinoma (RCC). KEYTRUDA® is a product of Merck & Co. Inc. and INLYTA® is a product of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
